Thera-SAbDab

IBRITUMOMAB

>   Structural Summary
TherapeuticIbritumomab
TargetMS4A1
Heavy ChainQAYLQQSGAELVRPGASVKMSCKASGYTFTSYNMHWVKQTPRQGLEWIGAIYPGNGDTSYNQKFKGKATLTVDKSSSTAYMQLSSLTSEDSAVYFCARVVYYSNSYWYFDVWGTGTTVTVSA
Light ChainQIVLSQSPAILSASPGEKVTMTCRASSSVSYMHWYQQKPGSSPKPWIYAPSNLASGVPARFSGSGSGTSYSLTISRVEAEDAATYYCQQWSFNPPTFGAGTKLELK
100% seqID Fv Structure3bky [Fvs: HL]
99% seqID Fv StructureNone
95-98% seqID Fv StructureNone
>   Metadata
FormatWhole mAb
IsotypeG1
Highest Clinical Trial (August '23)Approved
Estimated Status (August '23)NFD
Recorded Developmental Technologyna
INN Year Proposed1999
INN Year Recommended2000
Companies InvolvedBiogen, Schering, Spectrum Pharmaceuticals
Conditions ApprovedNon-Hodgkin's lymphoma
Conditions Activena
Conditions DiscontinuedDiffuse large B cell lymphoma, Mantle-cell lymphoma, Marginal zone B-cell lymphoma, Multiple myeloma
NotesSequence sourced through DrugBank. Thanks to HaeWon Chung for the contribution.

Schneider, C., Raybould, M.I.J., Deane, C.M. (2022) SAbDab in the Age of Biotherapeutics: Updates including SAbDab-Nano, the Nanobody Structure Tracker. Nucleic Acids Res. 50(D1):D1368-D1372 [link]

SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]

Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]

Our privacy policy